The Paul G. Allen Research Center, part of the Providence Swedish Cancer Institute in Seattle, opened Oct. 30. It was made possible with a $20 million donation from the center's namesake, a co-founder of Microsoft.
The Paul G. Allen Research Center, part of the Providence Swedish Cancer Institute on the health system's First Hill Campus in Seattle, opened Oct. 30.
The center was made possible through a $20 million donation from the late Paul G. Allen, a co-founder of Microsoft. It is the largest ever donation to Swedish Health Services, which is part of Providence St. Joseph Health.
The Paul G. Allen Research Center in Seattle divides research into three pillars: prevention, exploration and treatment.
The center's research is divided among three independent, but complimentary pillars: prevention, exploration and treatment. In traditional research models, one lab is established for one major researcher to guide the work. This new center is investigator agnostic — the center uses a competitive review model to select and mentor the most promising ideas from all Providence Swedish researchers, according to a press release.
Among early successes, team members opened the center's first clinical trial in February 2023 to examine the role of the drug Tarlatamab in lung cancer as part of a multicenter study. In May 2024, the therapy received Food and Drug Administration clearance as the first approved immunotherapeutic in its class.